HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial

Table 6 Relationship between anti-Tat or anti-Env Ab titers and Tat-mediated Env entry in DC in vaccinees

Parameter	Estimate	95 % CI		p value
Vaccinees
Anti-Tat IgM (log₁₀ titers)	−0.15	−0.31	0.02	0.0853
Anti-Tat IgG (log₁₀ titers)	−0.12	−0.20	−0.04	0.0039
Anti-Tat IgA (log₁₀ titers)	−0.02	−0.12	0.08	0.7579
Anti-Env IgG (log₁₀ titers)	−0.06	−0.09	−0.02	0.0015
Placebos
Anti-Env IgG (log₁₀ titers)	0.00	−0.02	0.02	0.9471

A longitudinal analysis for repeated measures by generalized estimating equation method was used for the analysis. Vaccinees anti-Tat Ab-positive n = 19 (86 observations), placebos anti-Tat Ab-negative n = 5 (30 observations)
CI confidence interval

ISSN: 1742-4690